Open
ADDF Drug Development RFP
Supports early Alzheimer’s therapeutic development
Last Update: June 25, 2026
Funding available
$ 5,000,000
Timeline
- Closing date : September 14, 2026
Location
Canada
Overview
The ADDF Drug Development RFP supports researchers and clinicians worldwide advancing Alzheimer’s disease and related dementia therapeutics. It funds IND-enabling studies and early-phase clinical trials for promising drugs, devices, and combination therapies.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Develop strategic partnerships
- Develop a new product or service
- Conduct research and development activities
Eligible Funding
- Maximum amount : 5,000,000 $
Timeline
- Closing date : September 14, 2026
Eligible candidates
Eligible Industries
- Health care and social assistance
Location
- Canada
Legal structures
- All legal structures
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- Startups
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- IND-enabling studies, including pharmacology, toxicology, pre-formulation, and GMP manufacture of API and/or drug product
- Preparation of traditional and exploratory IND applications
- Early-stage human clinical trials, including Phase 0, Phase 1, and biomarker-based proof-of-concept studies
- Long-term toxicology studies to enable longer-term dosing in phase 2 trials
- GMP manufacturing and testing of API and/or drug product required to move into phase 2 or phase 3 trials
Documents Needed
- Business packet (only for biotech companies)
- Budget and Justification
- Biosketches for each of the key personnel involved in the project
- Compound Report Card
- Human Subjects Questionnaire
Official resources
Eligibility
Who is eligible?
- Researchers and clinicians worldwide
- Academic medical centers and universities or nonprofits
- Biotechnology companies
- Existing companies and new startups
Eligible expenses
- Approved personnel costs
- Supplies, including consumables, chemicals, and animals
- Small non-durable equipment up to $2,500
- Consultants
- Patient costs related to clinical trials
Ineligible Costs and Activities
- Indirect costs/overhead
- Capital equipment
- Equipment service contracts
- Publication costs
- Travel, unless travel is pre-approved under special circumstances
Eligible geographic areas
- Worldwide
Selection criteria
- Proposals are assessed for consistency with the ADDF's mission and funding priorities.
- Invited full proposals are reviewed by external scientific and business review boards.
- For Therapeutics RFPs, resubmissions must address the reviewers' concerns with a point-by-point response.
How to apply
- Review the funding opportunities and carefully read the RFP.
- Read the Application and Funding Policies, including the Funding Mechanism section.
- Log in or create an account using the ADDF Funding Portal to begin the application process.
- Submit a Letter of Intent through the ADDF Funding Portal.
- If invited, submit a full proposal through the ADDF Funding Portal.
Processing and Agreement
- Letters of Intent are evaluated by ADDF’s science team to determine whether the proposed project is consistent with the ADDF's mission and funding priorities.
- Invited full proposals are reviewed by members of external scientific and business review boards.
- Proposals then undergo further due diligence by the ADDF science team and advisory boards to arrive at a final funding decision.
- All clinical trials receiving ADDF funding must register and submit results for applicable clinical trials on ClinicalTrials.gov.
- Institutions that receive funding from the ADDF are required to submit progress report materials using the appropriate templates.
Additional information
- Funding is provided through mission-related investments and terms of agreements may vary.
- Applications are reviewed in a two-step process: LOI first, then invited full proposal.
- Effective in 2026, full proposals must be submitted within the same cycle as the LOI.
- Applicants may be invited to resubmit Therapeutics RFP proposals up to two times if they address the reviewers' concerns.
Contacts
Frequently Asked Questions about the ADDF Drug Development RFP Program
What is the ADDF Drug Development RFP?
The ADDF Drug Development RFP supports researchers and clinicians worldwide advancing Alzheimer’s disease and related dementia therapeutics. It funds IND-enabling studies and early-phase clinical trials for promising drugs, devices, and combination therapies.
How much funding can be received?
ADDF Drug Development RFP Funds up to $5,000,000 of admissible expenses.
Who is eligible for the ADDF Drug Development RFP program?
To be eligible for the ADDF Drug Development RFP program, you must:
Funding is open to researchers and clinicians worldwide.
Academic medical centers and universities or nonprofits are eligible.
Biotechnology companies are eligible.
What expenses are eligible under ADDF Drug Development RFP?
IND-enabling studies, including pharmacology, toxicology, pre-formulation, and GMP manufacture of API and/or drug product
Preparation of traditional and exploratory IND applications
Early-stage human clinical trials, including Phase 0, Phase 1, and biomarker-based proof-of-concept studies
Long-term toxicology studies to enable longer-term dosing in phase 2 trials
GMP manufacturing and testing of API and/or drug product required to move into phase 2 or phase 3 trials
Who can I contact for more information about the ADDF Drug Development RFP?
You can contact Alzheimer's Drug Discovery Foundation (ADDF) by email at grants@alzdiscovery.org or by phone at 212.901.8000.
Where is the ADDF Drug Development RFP available?
The ADDF Drug Development RFP program is available across Canada.
Is the ADDF Drug Development RFP a grant, loan, or tax credit?
ADDF Drug Development RFP is a Grant and Funding